Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis

Hideo Morioka, Lawrence Weissbach, Tikva Vogel, G. Petur Nielsen, Glynn T. Faircloth, Li Shao, Francis J. Hornicek

研究成果: Article

70 引用 (Scopus)

抜粋

A combination therapy protocol using a marine chemotherapeutic and an antiangiogenic molecule was tested in a mouse tumor xenograft model for the ability to curtail the growth of a human chondrosarcoma (CHSA). Ecteinascidin-743 (ET-743), a marine-derived chemotherapeutic, was effective at slowing the growth of a primary CHSA. Plasminogen-related protein B, which antagonizes various endothelial cell activities, also elicited a significant inhibition of neoplastic growth, albeit with reduced effectiveness. The combination of the two agents resulted in only a modest further repression of tumor growth over that associated with ET-743 treatment alone, as measured by tumor volume (82% versus 76% inhibition, respectively). However, analysis of the extent of tumor necrosis and vascularization of the tumor revealed that the coadministration of the two compounds was clearly more effective, eliciting a 2.5-fold increase in tumor necrosis relative to single-agent treatment. The combination therapy also was most effective at antagonizing tumor-associated microvessel formation, as assessed by CD31 immunostaining, suggesting that combination therapy may hold promise for treating CHSA. Tumor necrosis produced by combination therapy of ET-743 and recombinant plasminogen-related protein B was also significantly greater than that produced by conventional doxorubicin treatment, further corroborating the efficacy of combination therapy.

元の言語English
ページ(範囲)1211-1217
ページ数7
ジャーナルClinical Cancer Research
9
発行部数3
出版物ステータスPublished - 2003 3 1

    フィンガープリント

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

これを引用

Morioka, H., Weissbach, L., Vogel, T., Nielsen, G. P., Faircloth, G. T., Shao, L., & Hornicek, F. J. (2003). Antiangiogenesis treatment combined with chemotherapy produces chondrosarcoma necrosis. Clinical Cancer Research, 9(3), 1211-1217.